ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
107,872.68
4.62%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU

  6. Vivoryon Therapeut (VVY) 시세

Vivoryon Therapeut

Vivoryon Therapeut (VVY)

EU
2.025
0.00
(0.00%)
마감 20 1월 1:30AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
2.025
매수가
2.00
매도가
2.03
거래량
0.00
0.00 일간 변동폭 0.00
0.41 52주 범위 9.93
market_cap
-
전일 종가
2.025
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
177,830
발행 주식
0.00
배당수익률
-
주가수익률
0.00
주당순이익(EPS)
-
매출
-3.62M
순이익
-28.34M

Vivoryon Therapeut 정보

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.vivoryon.com
본부
Halle, Deu
설립됨
-
Vivoryon Therapeut is listed in the Biological Pds,ex Diagnstics sector of the 유로넥스트 (Euronext) with ticker VVY. The last closing price for Vivoryon Therapeut was 2.03 €. Over the last year, Vivoryon Therapeut shares have traded in a share price range of 0.41 € to 9.93 €.

Vivoryon Therapeut currently has 0 shares in issue.

VVY 최신 뉴스

추가 뉴스

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

09 12월 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

04 12월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

26 10월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

11 10월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

01 10월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

12 9월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

06 9월 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

05 9월 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

18 7월 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Halle (Saale) / Munich, Germany, July 9, 2024 - Vivoryon Therapeutics N.V. (Euronext...

09 7월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.0251.2522.251.931101282.03134664DE
40.0753.846153846151.952.251.931149822.04964546DE
12-0.485-19.32270916332.512.71.671778302.17003516DE
26-0.31-13.27623126342.3352.9951.672059122.29379235DE
52-5.615-73.49476439797.649.930.415648381.96667609DE
156-13.195-86.695137976315.2219.560.412302473.68475912DE
260-4.505-68.9892802456.5323.250.411743395.02809174DE

VVY - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeut share price?
The current share price of Vivoryon Therapeut is 2.025 €
What is the 1 year trading range for Vivoryon Therapeut share price?
Vivoryon Therapeut has traded in the range of 0.41 € to 9.93 € during the past year
What is the reporting currency for Vivoryon Therapeut?
Vivoryon Therapeut reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeut?
The latest annual turnover of Vivoryon Therapeut is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeut?
The latest annual profit of Vivoryon Therapeut is EUR -28.34M
What is the registered address of Vivoryon Therapeut?
The registered address for Vivoryon Therapeut is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeut website address?
The website address for Vivoryon Therapeut is www.vivoryon.com
Which industry sector does Vivoryon Therapeut operate in?
Vivoryon Therapeut operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ABCAABC Arbitrage
4.805 €
(0.00%)
0
ABAb Science
1.75 €
(0.00%)
0
AALBAalberts NV
34.20 €
(0.00%)
0
AAAAlan Allman Associates
7.35 €
(0.00%)
0
74SW74Software SA
27.10 €
(0.00%)
0
ABCAABC Arbitrage
4.805 €
(0.00%)
0
ABAb Science
1.75 €
(0.00%)
0
AALBAalberts NV
34.20 €
(0.00%)
0
AAAAlan Allman Associates
7.35 €
(0.00%)
0
74SW74Software SA
27.10 €
(0.00%)
0
ABCAABC Arbitrage
4.805 €
(0.00%)
0
ABAb Science
1.75 €
(0.00%)
0
AALBAalberts NV
34.20 €
(0.00%)
0
AAAAlan Allman Associates
7.35 €
(0.00%)
0
74SW74Software SA
27.10 €
(0.00%)
0

토론

전체 피드 보기
weedtrader420 weedtrader420 9 초 전
WOOHOOOOOOOOOOOOOOO
BTCUSD
JamesLH JamesLH 2 분 전
🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡
SNPW
BDEZ BDEZ 8 분 전
U see this yet? https://x.com/WallStreetApes/status/1881033029382193613
BDEZ BDEZ 9 분 전
For sure...
ATDS FB CULT ATDS FB CULT 11 분 전
Anyone else watching this history live,?
Haven't watched a squeeze live like that in long time. Fun fun fun
Looks like lucky 1's are coming right up
BTCUSD
Sheepdog Sheepdog 13 분 전
"This board" was first started in July of 2018.

Should be an easy check before posting BS, right?
.
GCAN
BDEZ BDEZ 15 분 전
Karen Bass history https://x.com/RealJamesWoods/status/1880769377110552691
BDEZ BDEZ 17 분 전
We are being played https://x.com/WallStreetApes/status/1880834013067149780
BDEZ BDEZ 19 분 전
U see this kid? https://x.com/QueenAnticommie/status/1881170030592958882
BDEZ BDEZ 20 분 전
Thanks for sharing...
knrorrel knrorrel 30 분 전
AWESOME ❤️
JTBK
knrorrel knrorrel 32 분 전
SOUNDS GREAT
JTBK
igotthemojo igotthemojo 36 분 전
"Companies that employ a tactic to avoid delisting by destroying value SHOULD BE a crime (which were my exact words)"

no...those were not your exact words...these were your exact words:

"A company that defrauds investors like that should be sued and delisted."
FCEL
joeycav11 joeycav11 44 분 전
Flipper you have to have faith that management knows what they are doing. Approval allows promotion and advertising of DCVax. A new revolutionary product.
People and companies will be fighting to be associated with this paridigm shift.
What I see happening is news flow coming out sl
NWBO
JoeForkeyBolo JoeForkeyBolo 46 분 전
Jeff Weber's method of using AIM with LEAPs rolls over the options annually, with the LEAPs being rolled over have expirations about 1 year away, and are exchanged for LEAPs having expirations 2 years away. The time decay in the last 6 months prior to expiration should have no impact on Weber's meth
QQQ
SuperStream852 SuperStream852 47 분 전
It sounds like you're using humor and metaphor to express frustration with a situation where you're losing money, but you don't believe the source is the pants themselves. Instead, you're hinting at external factors or entities that might be influencing the situation, potentially in a way that seems
PTOI
holter49 holter49 47 분 전
I hope you are correct and we do sky.
MLRT
KILLAZILLA KILLAZILLA 51 분 전
LOLOLOLOL....

YET, STILL DOWN OVER 80%....

GOOD JOB. BETTER THAN DONE 90%....

UNFORTUNATELY, WHEN THIS POS SCAM GETS DELISTED OR GOES DARK, NO MORE HOPE!!!!
XERI
amelia43 amelia43 52 분 전
Market is closed tomorrow. MLK
FNMA
Steady_T Steady_T 55 분 전
I don't use Think or Swim. I loaded it and worked with it for a few days and decided I didn't care for it. From the TOS search page...
Tick Charts
Tick charts represent the count of intraday trades: a new bar (or candlestick, line section, etc.) is plotted after completion of a certain
NWBO
amelia43 amelia43 58 분 전
Welcome back Arnold finally. Is cousin alongz dead?
FNMA
Alexulf Alexulf 59 분 전
Yes, brother, he does. It's funny :-) it seems a minority support the company/stock—or maybe some do it in silence? The arguments for and against the CEO, the products, etc. create a lot of polarisation on the board. Just curious, how do you manage to keep up with it (bashing), and no, I`m still not
AITX

최근 히스토리

EU
VVY
Vivoryon Therapeut
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유